


Date of Preparation: Oct 2024



Signature

Ayesha B. Alvero, M.D., M. Sc.

Office Address: 275 E. Hancock St. Detroit, MI 48201

Office Telephone: (313) 577-1794

E-mail Address: ayesha.alvero@wayne.edu

EDUCATION M. Sc. Molecular and Cellular Biology , University of New Haven, West Haven, CT, USA M.D. University of the East, Manila, Philippines B.S. Biology , De La Salle University, Manila, Philippines	DATES 2003 1996 1992
POSTGRADUATE TRAINING Post-doctoral Fellowship , Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University, New Haven, CT, USA Post-doctoral Fellowship , Department of Therapeutic Radiology, Yale University, New Haven, CT, USA Research Internship , Department of Therapeutic Radiology, Yale University, New Haven, CT, USA Medical Internship , University of the East, Manila, Philippines	2003-2006 2001-2003 2000-2001 1996-1997
FACULTY APPOINTMENTS Professor Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI Department of Oncology, Wayne State University, Detroit, MI Senior Research Scientist , Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University, New Haven, CT, USA Research Scientist , Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University, New Haven, CT, USA Associate Research Scientist , Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University, New Haven, CT, USA	2019-Present 2024-Present 2018-2019 2012-2018 2006-2012
HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS Paramedical Examiner Paramedical Services of America Rocky Hill, CT	1999-2001
MAJOR PROFESSIONAL SOCIETIES American Association for Cancer Research	2003-Present

<p>SERVICE</p> <p>Scholarly Service</p> <p>Service for Peer-Reviewed Journals Review of Manuscripts: Clinical Cancer Research, Gynecologic Oncology, Expert Review of Anticancer Therapy, Epigenomics, American Journal of Reproductive Immunology, Scientific Reports, Expert Opinion on Drug Metabolism and Therapy, Oncotarget, British Journal of Cancer, Communications Biology, Cell death and Disease, Translational Oncology</p> <p>Associate Editor, Systems Biology in Reproductive Medicine Guest Editor, Cancers Ad Hoc Grant Reviewer, National Institute of Standards and Technology, U.S. Department of Commerce</p>	<p>2008 – Present</p> <p>2020 – Present</p> <p>2024</p> <p>2024</p>
<p>Other Service</p> <p>Yale University Discovery to Cure High School Internship Program: Committee Member for evaluation and selection of participants Member, Executive Committee: C.S. Mott Center Member, Education Committee: C.S. Mott Center Member, Recruitment Committee: C.S. Mott Center Co-Chair, Equipment and Space Committee: C.S. Mott Center Director, Ovarian Cancer Research Program: C.S. Mott Center Member, Carogen Scientific Advisory Board Reviewer, MARTS Meeting Chair, Seminars and Retreat Committee: C.S. Mott Center Organizer, MARTS Meeting External Committee Member, Courtney Condor Thesis (Dept. of Chemistry) Resident Interviews, Dept. of Obstetrics and Gynecology, WSU Director, Discovery to Cure High School Internship Program Member, Seminar Committee: C.S. Mott Center Chair, Social Events Committee: C.S. Mott Center Chair, Ovarian Cancer Symposium: C.S. Mott Center Chair, Trainee Research Day: C.S. Mott Center Member, Wayne Undergraduate Cancer Research Group Lead, Gynecologic Oncology Resident Research Group</p>	<p>2005 – Present</p> <p>2019 – Present</p> <p>2019 – Present</p> <p>2019 – Present</p> <p>2019 – 2023</p> <p>2020 – Present</p> <p>2021 - Present</p> <p>2021, 2022, 2023</p> <p>2019 – 2023</p> <p>2022</p> <p>2022</p> <p>2022</p> <p>2023 – Present</p> <p>2023 – Present</p> <p>2023 – Present</p> <p>2023</p> <p>2024</p> <p>2024</p> <p>2024</p>

<p>TEACHING</p> <p>Teaching at Wayne State University PSL 7690 Principles of Reproductive Biology PSL 7775 Current Research Topics in Reproductive Science MGG 7091 Scientific Communication Mock Study Section</p> <p>Teaching at Other Institution Graduate students: University of New Haven, MB611, Molecular Biology of Proteins with Laboratory, Instructor Residents/Fellows: Yale University, Organ site lecture series, Pathology Department, Lecturer</p>	<p>2019 – Present 2021 - Present 2022 – Present</p> <p>2007 – 2012 2018</p>
<p>Mentorship</p> <p><u>Residents and Clinical Fellows:</u></p> <p>Danielle Arias * Sialylation as an immune checkpoint in ovarian cancer 2024</p> <p>Terrence Wong, MD * Targeting the adipose microenvironment in ovarian cancer 2022 - 2023</p> <p>Alexander Paridon, MD * Novel UPR-inducers as treatment for chemoresistant ovarian cancer 2019– 2020</p> <p>Christopher Walker * Biomarkers for early detection of ovarian cancer 2020-2021</p> <p>Marta Gurrea-Soteras, MD * Identification of novel signals for malignant transformation of ovarian surface epithelial cells 2011-2012</p> <p>Aliza Leiser, MD * Identification and characterization of novel NFkB inhibitor for the treatment of chemoresistant ovarian cancer cells 2006-2007</p> <p>Dan-Arin Silasi, MD * Development of diagnostic parameters to use MyD88 expression as biomarker for Paclitaxel resistance 2005-2006</p> <p>Michael Kelly, MD * Identification and characterization TLR4-MyD88 pathway in Paclitaxel resistance 2004-2005</p> <p><u>Post-doctoral associates:</u></p> <p>Shlomit Jessel, PhD * Characterization of adipocyte-induced chemoresistance pathway 2017-2018</p> <p>Carlos Cardenas, MD * Identification of distinct of Bcl2 family proteins and their relevance in different subtypes of ovarian cancer cells 2015-2017</p> <p>Guy Nadel, PhD * Characterization of molecular mechanisms of MIF and NV128-induced cell death in ovarian cancer cells 2008-2010</p> <p><u>Visiting Scholars:</u></p> <p>Boseong Yun, MD * Role of ovulation-induced factors in ovarian cancer progression 2015-2016</p> <p>Wonduk Joo, MD * Role of Prolactin and Leptin in ovarian cancer progression 2011-2013</p>	

Kim Kyungjin, MD * Validation of CD44 as marker of chemoresistance in ovarian cancer	2006-2007
Ki Hyung Kim, MD * Value of ERK inhibitors in ovarian cancer	2004-2006
Jian Jun Li, MD * Characterization of molecular mechanisms of NV6-induced cell death	2003-2004
<u>Medical students:</u>	
Ramalakshmi Thulluri * Role of sialylation in the ovarian tumor microenvironment	2022- 2023
Juanni Li * Role of PRC proteins in ovarian cancer metastasis	2014-2016
Sean Orton * Development of novel diagnostic modalities for the detection of micrometastasis in ovarian cancer	2014
Sarah Steinmacher * Characterization of molecular mechanisms of Cantrixil-induced cell death	2014-2015
Jaime Green * Identification and characterization of isoflavone derivatives for the treatment of chemoresistant ovarian cancer cells	2009-20010
<u>Graduate students:</u>	
Natalia Sumi * Characterization of molecular mechanisms of Cantrixil-induced cell death	2013-2015
Vinicius Craveiro * Development of novel mouse model for recurrent ovarian cancer	2012-2013
Hsuan Fu * Development of diagnostic parameters to use MyD88 expression as biomarker for Paclitaxel resistance	2009-2011
Adife Gulhan Ercan, PhD * Gene expression signature induced by progesterone in ovarian surface epithelial cells	2002
Bambang Dwipoyono, MD * Ck19 as biomarker for circulating breast cancer cells	2001
<u>PhD students:</u>	
Hussein Chehade * Adipocyte-induced mechanisms of ovarian cancer metastasis	2019 – 2023
Nicholas Adzibolosu * Transcriptomic predictors of response in ovarian cancer	2021 – Present
Garry Leonard * Role of sialylation in ovarian tumor microenvironment	2021 - Present
<u>Undergraduate students:</u>	
Marcia Manaloto * Differential sialylation status in BRCA1 and BRCA2 mutant ovarian cancers	2023

Serena Chan * Development and validation of novel caspase activity assay	2003-2004
Emma Graham * Characterization of molecular mechanisms of NV128-induced cell death	2012
Kennedy McGhee * Characterization of novel p53-targeting compounds in the treatment of ovarian cancer	2018
Marcia Manaloto * Differential tumor immune-microenvironment in BRCA1 and BRCA2 ovarian tumors	2023
<u>High school students:</u>	
Shrina Patel * Value of proteasome inhibitors in ovarian cancer	2003
Michelle Tong * Value of Akt inhibitors in ovarian cancer	2003
Merrill Brady * Characterization of novel small-molecule compounds in the treatment of ovarian cancer	2005 2006
Jessica Oidtman * Ovarian cancer stem cells as vascular progenitors	2007
Kelsey Sokol * Characterization of novel small-molecule compounds in the treatment of ovarian cancer	2009
Marissa Matthews * Characterization of novel small-molecule compounds in the treatment of ovarian cancer	2009
Sean Barwis * Characterization of novel small-molecule compounds in the treatment of ovarian cancer	2015
William Rooney * Characterization of molecular mechanisms of Cantrixil-induced cell death	2016
Shawn Jayee * Role of MNRR1 in ovarian cancer	2021
Aryan Singh * Regulation of MNRR1 in ovarian cancer	2022
Jenna Hopgood * Cellular partners of MNRR1 in ovarian cancer	2023

GRANTS, CONTRACTS, AND OTHER FUNDING

Active National/International Grants and Contracts

Role: PI, Percent effort: 10%

Title: Metabolic adaptation as a mechanism for chemoresistance in ovarian cancer

Source: The Janet Burros Memorial Foundation

10/01/2021 – 09/30/2025

Direct costs per year: \$ 125,000

Total direct costs: \$500,000

Role: Co-I, Percent effort: 10%

PI: Gil Mor

Title: Evaluation of CARG-2020 in vitro and in vivo efficacy

Source: Carogen

06/01/2022 – 12/01/2024

Total direct costs: \$100,000

Role: PI, Percent effort: N/A, no salary support

Title: Mechanisms of adipose-induced cancer cell sialylation and development of immune tolerance

Source: Karmanos Cancer Institute

Direct costs per year: \$ 50,000

Pending Grants

Role: PI, Percent effort: 20%

Title: Specific targeting of sialylation in the ovarian tumor microenvironment for improved anti-tumor immune response

Source: Department of Defense

Direct costs per year: \$ 170,000

Total direct costs: \$ 669,717

Role: PI, Percent effort: N/A, no salary support

Title: Sialylation: An Emerging Immune Checkpoint in Ovarian Cancer

Source: Michigan Ovarian Cancer Alliance

Direct costs per year: \$ 50,000

Total direct costs: \$ 50,000

Role: Co-I, Percent effort: 30%

Title: Oncolytic VLV-based immunotherapy for ovarian cancer

Source: NCI

Direct costs per year: \$ 1,042,515

Total direct costs: \$ 2,085,030

Previously Funded Grants and Contracts

Role: PI, Percent effort: N/A, no salary support

Title: Impact of BRCA mutation on ovarian tumor microenvironment

Source: Karmanos Cancer Institute

Direct costs per year: \$ 50,000

Role: Co-investigator, Percent effort: 50% R01 CA199004

PI: Gil Mor, MD, PhD

Title: "Targeting the vascularity for delivery of inhibitors of metastasis in ovarian cancer." The goal of this study is to understand the mechanisms associated with ovarian cancer metastasis and develop novel approaches to inhibit it.

Source: National Institutes of Health, National Cancer Institute

07/06/2015 – 06/30/2021

Direct costs per year: \$ 636,016

Total direct costs: \$ 3,180,000

Role: PI, Percent effort: 10%

Title: "Novel diagnostic and therapeutic modalities for recurrent ovarian cancer." The goal of this study is to develop novel diagnostic and therapeutic approaches to prevent recurrent ovarian cancer.

Source: Discovery to Cure

03/01/2017 – 02/28/2019

Total direct costs: \$ \$ 100,000

Role: PI, Percent effort: 10%

Title: "New approaches for detection and treatment of ovarian cancer." The goal of this study is to develop novel diagnostic and therapeutic approaches to treat ovarian cancer.

Source: Sands Family Foundation

04/01/2016 – 03/31/2019

Total direct costs: \$150,000

Role: PI , Percent effort: 10% R01

Title: "Enhanced detection of ovarian cancer micrometastasis for optimal surgical debulking." The goal of this study is to develop a novel diagnostic modality for the visualization and delineation of micrometastatic ovarian cancer.

Source: Discovery to Cure

01/01/2015 – 12/31/2015

Total direct costs: \$50,000

Role: Co-PI, Percent effort: 30%

PI: Gil Mor, MD, PhD

Title: "New therapies for cancer stem cells." The goal of this study is to identify novel therapies that target chemoresistant ovarian cancer stem cells.

Source: CanTx

07/01/2013 – 06/30/2016

Total direct costs: \$ 1.5M

Role: Co-investigator, Percent effort: 50% R01 CA127913

PI: Gil Mor, MD, PhD

Title: "MyD88 bearing tumors in immune regulation and chemoresistance." The goal of this study is to determine the role of TLR-MyD88 signaling pathway in the immune regulation and acquisition of chemoresistance.

Source: National Institutes of Health, National Cancer Institute

7/1/2008 to 6/30/2013

Direct costs per year: \$250,000

Total direct costs: \$2,068,021

Role: Co-investigator, Percent effort: 50% R01 CA97237

PI: Gil Mor, MD, PhD

Title: "Apoptotic regulators in ovarian cancer." The goal of this study is to identify and target key apoptotic regulators in chemoresistant ovarian cancer cells.

Source: National Institutes of Health, National Cancer Institute

8/13/2007 to 7/31/2012

Direct costs per year: \$190,000

Total direct costs: \$1,571,380

PATENTS

United States Patent Application Number: US20170281588

Date: 2017-10-05

Title: Compositions and Methods for Treating Epithelial Cancer

Role: Co-Inventor

Patent number: EP2953938A1

Date: 2014-02-07

Title: Functionalised benzopyran compounds and use thereof

Role: Co-Inventor

United States Patent Application Number: US2012251630

Date: 2012-10-04

Title: Remission therapy of cancer with isoflavonoids

Role: Co-Inventor

PUBLICATIONS

Peer-Reviewed Publications

Reports of Original Work

*student

** trainee/fellow/scholar

1. Fox A, *Leonard G, **Adzibolosu N, **Wong T, Tedja R, Sharma S, Gogoi R, Morris R, Mor G, Fehl C, **Alvero AB**. Adipose microenvironment promotes hypersialylation of ovarian cancer cells. *Front Oncol*, 2024, July 222. doi: 10.3389/fonc.2024.1432333.
2. *Chehade H, Gogoi R, *Adzibolosu N, Galoforo S, Fehmi R, Kheil M, Fox A, Kim S, Rattan R, Hou Z, Morris R, Matherly L, Mor G, **Alvero AB**. BRCA status dictates Wnt responsiveness in epithelial ovarian cancer. *Cancer Res Commun*, 2024, Aug 1; 4(8):2075-2088. doi: 10.1158/2767-9764.CRC-24-0111.
3. **Wong T, Tedja R, *Chehade H, Morris R, **Alvero AB**, Mor G. An ex vivo model of ovarian cancer peritoneal metastasis using human omentum. *J Vis Exp*. 2024 Jan 26; (203). doi: 10.3791/66031.
Role: manuscript writing and editing
4. **Alvero AB**, Fox A, Madina B, Krady M, Gogoi R, Chehade H*, Nakaar V, Almassian B, Yarovinsky T, Rutherford T, Mor G. Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory. *Cancer Immunol Res*, 2023, Dec 11. doi: 10.1158/2326-6066.CIR-23-0127.
5. Zhang Y, Tedja R, Millman M, Wong T**, Fox A, Chehade H*, Gershater M*, Adzibolosu N*, Gogoi R, Anderson M, Rutherford T, Zhang Z, Chopp M, Mor G, **Alvero AB**. Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells. *J Ovarian Res*, 2023; 16 (1): 233.
6. Gogoi R, Galoforo S, Fox A, Morris C*, Ramos H*, Gogoi V, Chehade H*, Adzibolosu N*, Shi C, Zhang J, Tedja R, Morris R, **Alvero AB**, Mor G. A Novel Role of Connective Tissue Growth Factor in the Regulation of the Epithelial Phenotype. *Cancers*, 2023; 15(19): 4834.
Role: study design and manuscript writing
7. Tedja R, **Alvero AB**, Fox A, Cardenas C, Pitruzzello M, Chehade H*, Bawa T*, Adzibolosu N*, Gogoi R, Mor G. Generation of Stable Epithelial–Mesenchymal Hybrid Cancer Cells with Tumorigenic Potential. *Cancers*, 2023; 15(3):684.
Role: study design, data analysis, manuscript writing
8. Adzibolosu N*, **Alvero AB**, Ali-Fehmi R, Gogoi R, Corey L**, Tedja R, Chehade H, Gogoi V, Morris R, Anderson M, Vitko J, Craig DB, Draghici S, Rutherford T, Mor G. Immunological modification following chemotherapy are associated with delayed recurrence in ovarian cancer. *Front Immunol*. 2023; 14:1204148.
Role: study design, data analysis, project administration, manuscript writing and editing

9. You Y, Grasso E, **Alvero A**, Condon J, Dimova T, Hu A, Ding J, Alexandrova M, Manchorova D, Dimitrova V, Liao A, Mor G. Twist1-IRF9 interaction is necessary for IFN-stimulated gene anti-Zika viral infection. *J Immunol*: 2023; May 5:ji2300081.
Role: study design, data analysis, manuscript writing
10. H Chehade*, N Adzibolusu*, S Jayee*, A Singh*, R Tedja, R Gogoi, S Aras, L Grossman, G Mor , **A Alvero**. MNR1 is a driver of ovarian cancer progression. *Translational Oncology*. 2023 Mar;29:101623.
11. Saed G, Nawaz A, **Alvero A**, Harper A, Morris R. Monomeric myeloperoxidase is a specific biomarker for early-stage ovarian cancer. *Biomarkers*, 2023, dec; 28(7): 663-671. doi: 10.1080/1354750X.2023.2284106.
Role: data analysis
12. Liu J, Shu G, Wu A, Zhang X, Zhou Z, **Alvero A**, Mor G, Yin G. TWIST1 induces proteasomal degradation of β -catenin during the differentiation of ovarian cancer stem-like cells. *Scientific Reports*. 2022 Sep 19;12(1):15650.
Role: study design
13. van den Pol AN, Zhang X, Lima E, Pitruzzello M, **Alvero A**, Davis JN, Mor G. Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response. *Virology*. 2021 Mar;555:44-55.
Role: study design, project administration and manuscript writing
14. Maxwell AJ, Ding J, You Y, Dong Z, Chehade H*, **Alvero A**, Mor Y, Draghici S, Mor G. Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients..*Journal of leukocyte biology*. 2021 Jan;109(1):35-47.
Role: study design
15. Walker C**, Nguyen TM, Jessel S, **Alvero AB**, Silasi DA, Rutherford T, Draghici S, Mor G. Automated Assay of a Four- Protein Biomarker Panel for Improved Detection of Ovarian Cancer. *Cancers*. 2021 Jan 17;13(2):325. Role: study desing, project administration, manuscript writing
16. Mary P. Udumula, Sharif Sakr, Sajad Dar, **A Alvero**, R Ali-Fehmi, Eman Abdulfatah, Jing L, Jun Jiang, A Tang, R Morris, Ramandeep Rattan. Ovarian cancer modulates the immunosuppressive function of CD11b + Gr1 + myeloid cells via glutamine metabolism. *Mol Metab*. 2021. Nov;53:101272. Role: manuscript writing
17. **Alvero AB**, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Han P, Edelson RL, Mor G. Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. *Oncoimmunology*. 2020 May 13;9(1):1758869.

18. **Li J, **Alvero AB**, Nuti S, Tedja R, Roberts CM, Pitruzzello M, Li Y, Xiao Q, Zhang S, Gan Y, Wu X, Mor G, Yin G. CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. *Oncogene* 2020; doi: 10.1038/s41388-020-1269-5
Role: study design, data analysis, manuscript writing
19. Tedja R, Roberts C, **Alvero AB**, **Cardenas C, Yang-Hartwich Y, *Spadinger S, Pitruzzello M, Yin, G, Glackin CA, and Mor G. Protein kinase C α -mediated phosphorylation of Twist1 at Ser-144 prevents Twist1 ubiquitination and stabilizes it. *J Biol Chemistry* 2019; 294(13):5082-5093.
Role: study design, data analysis, manuscript writing
20. Yang-Hartwich Y, Tedja R, Roberts C, Goodner-Bingham J, **Cardenas C, **Gurrea-Soteras M, **Sumi N, **Alvero AB**, Glackin C, and Mor G. p53-Pirh2 complex promotes Twist1 degradation and inhibits EMT in ovarian cancer cells. *Mol Cancer Res* 2019; 17(1):153-164.
Role: data analysis, manuscript writing
21. **Alvero AB**, Kim D, Lima E, **Sumi NJ, Lee JS, **Cardenas C, Pitruzzello M, Silasi DA, Buza N, Fahmy T, Mor G. Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model. *Sci Rep* 2017; 7:40989.
22. **Cardenas C, Montagna MK, Pitruzzello M, Lima E, Mor G, **Alvero AB**. Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells. *Apoptosis* 2017; 22(4):558-569.
23. Fu X, Li Y, **Alvero A**, Li J, Wu Q, Xiao Q, Peng Y, Hu Y, Li X, Yan W, Guo K, Zhou W, Wang Y, Liu J, Zhang Y, Mor G, Wen J, Yin G. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. *Oncotarget* 2016; 7(49):80633-80654.
Role: study design, data analysis
24. **Alvero AB**, Heaton A, Lima E, Pitruzzello M, Sumi N, Yang-Hartwich Y, **Cardenas C, *Steinmacher S, Silasi DA, Brown D, Mor G. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. *Mol Cancer Ther* 2016; 15(6):1279-90.
25. Yang-Hartwich Y, **Soteras MG, Lin ZP, Holmberg J, **Sumi N, **Craveiro V, **Liang M, *Romanoff E, Bingham J, Garofalo F, **Alvero A**, Mor G. p53 protein aggregation promotes platinum resistance in ovarian cancer. *Oncogene* 2015; 34(27):3605-16.
Role: study design, data analysis
26. Yang-Hartwich Y, **Gurrea-Soteras M, **Sumi N, **Joo WD, Holmberg JC, **Craveiro V, **Alvero AB**, Mor G. Ovulation and extra-ovarian origin of ovarian

cancer. *Sci Rep* 2014; 4:6116.
Role: study design, data analysis

27. **Alvero AB**, Montagna MK, **Sumi NJ, ***Joo WD, Graham E, Mor G. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. *Oncotarget* 2014;5 (18):8703-15.
28. **Sumi NJ, Lima E, Pizzonia J, *Orton SP, **Craveiro V, **Joo W, Holmberg JC, **Gurrea M, Yang-Hartwich Y, **Alvero A**, Mor G. Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence. *J Vis Exp* 2014;(93):e51815.
Role: study design, data analysis, manuscript writing
29. **Craveiro V, Yang-Hartwich Y, Holmberg JC, **Sumi NJ, Pizzonia J, Griffin B, Gill SK, Silasi DA, Azodi M, Rutherford T, **Alvero AB**, Mor G. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. *Cancer Med* 2013; 2 (6): 751-62.
Role: study design, data analysis, manuscript writing
30. Chefetz I, **Alvero AB**, Holmberg JC, et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. *Cell Cycle* 2013; 16;12(3).
Role: study design, acquisition of data, data analysis, manuscript writing
31. **Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, **Alvero AB**, and Silasi DA. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. *Reprod Sci* 2013; 20 (5): 605-15.
Role: study design, data analysis
32. Yin G, **Alvero AB**, **Craveiro V, et. al. Constitutive proteasomal degradation of TWIST-1 in epithelial- ovarian cancer stem cells impacts differentiation and metastatic potential. *Oncogene* 2012; 32 (1):39-49.
*Role: study design, acquisition of data, data analysis, manuscript writing
33. Pizzonia J, Holmberg J, *Orton S, **Alvero AB**, et al. Multimodality animal rotation imaging system (Mars) for in vivo detection of intraperitoneal tumors. *Am J Reprod Immunol.* 2012; 67(1):84-90.
Role: study design, data analysis
34. **Alvero AB**, Montagna MK, **Craveiro V, et al. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. *Am J Reprod Immunol.* 2012; 67(3): 256-65.
35. Ramhorst R, Fraccaroli L, Aldo P, **Alvero AB**, et al. Modulation and recruitment of inducible regulatory T cells by first trimester trophoblast cells. *Am J Reprod Immunol.* 2012; 67(1):17-27.
Role: study design, acquisition of data, data analysis

36. **Steffensen K, **Alvero AB**, Waldstom Marianne, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early stage ovarian cancer. *J Oncol.* 2011; online.
Role: study design, acquisition of data, data analysis
37. **Alvero AB**, Montagna MK, Holmberg JC, et. al. Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells. *Mol Cancer Ther.* 2011; 10(8):1385-93.
38. Wang X, McKernan R, Kim KH, **Alvero AB**, et al. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. *Anticancer Drugs*, 2011;online.
Role: study design, acquisition of data, data analysis
39. Chefetz I, Holmberg JC, **Alvero AB**, et al. Inhibition of Aurora A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFkB pathway. *Cell Cycle*, 2011; online.
Role: study design, acquisition of data, data analysis
40. Hanlon DJ, Aldo PB, Devine L, **Alvero AB**, et al. Enhanced Stimulation of Anti-Ovarian Cancer CD8(+) T Cells by Dendritic Cells Loaded with Nanoparticle Encapsulated Tumor Antigen. *Am J Reprod Immunol.* 2011; 65(6): 597-609.
Role: study design, acquisition of data, data analysis
41. **Leizer AL, **Alvero AB**, et al. Regulation of Inflammation by the NF-κB Pathway in Ovarian Cancer Stem Cells. *Am J Reprod Immunol.* 2010; 65(4): 438-47.
Role: study design, acquisition of data, data analysis, manuscript writing
42. Yin G, *Chen R, **Alvero AB**, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. *Oncogene.* 2010; 29(24): 3545-53.
Role: study design, acquisition of data, data analysis
43. Straszewski-Chavez SL, Abrahams VM, **Alvero AB**, Aldo PB, Ma Y, Guller S, Romero R, Mor G. The isolation and characterization of a novel telomerase immortalized first trimester trophoblast cell line, Swan 71. *Placenta.* 2009; 30(11): 939-48.
Role: study design, acquisition of data, data analysis
44. **Alvero AB**, **Fu HH, Holmberg J, et al. Stem-like ovarian cancer cells can serve as vascular progenitors. *Stem Cells.* 2009; 27(10): 2450-13.
45. **Kim, KH, Xi, Y, Tytler, EM, Woessner, R, Mor, G, **Alvero, AB**. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. *J Transl Med.* 2009; 7: 63.
46. *Green, JM, **Alvero, AB**, et al. 7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: a novel compound capable of inducing cell death in epithelial

ovarian cancer stem cells. *Cancer Biol Ther.* 2009; 8(18): 1747-53.

Role: study design, data analysis, manuscript writing

47. **Alvero, AB**, Montagna, MK, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through Akt/mTOR pathway. *Cancer.* 2009; 115(14): 3204-16.
48. **Alvero, AB**, Chen R, **Fu HH, Montagna MK, et al. Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. *Cell Cycle.* 2009; 8(1): 158-66.
49. *Chen R, **Alvero AB**, **Silasi DA, **Kelly MG, Fest S, Visintin I, **Leiser A, Schwartz PE, Rutherford T, and Mor G. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. *Oncogene.* 2008; 27(34):4712-23.
Role: study design, acquisition of data, data analysis, manuscript writing
50. Visintin I, Feng Z, Longton G, Ward SC, **Alvero AB**, et al. Diagnostics markers for early detection of ovarian cancer. *Clin Cancer Res.* 2008; 14(4): 1065-1072.
Role: study design, data analysis
51. **Agarwal R, Whang DH, **Alvero AB**, Visintin I, Lai Y, Segal EA, Schwartz P, Ward D, Rutherford T, Mor G. Macrophage migration inhibitory factor expression in ovarian cancer. *Am J Obstet Gynecol.* 2007; 196(4); 348.e1-5.
Role: study design, acquisition of data, data analysis, manuscript writing
52. **Alvero AB**, Brown D, Montagna M, *Matthews M, and Mor G. Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. *Cancer Biol Ther.* 2007; 6(4): 612-617.
53. Kluger HM, McCarthy MM, **Alvero AB**, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. *J Transl Med* 2007.; 5(1):6.
Role: study design, acquisition of data, data analysis
54. **Fest S, Aldo PB, Abrahams VM, Visintin I, **Alvero A**, **Chen R, Chavez SL, Romero R, and Mor G. Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. *Am J Reprod.* 2007; 57(1): 55-66.
Role: study design, acquisition of data, data analysis
55. **Kelly MG, **Alvero AB**, Chen R, Abrahams VM, Chan S, Visintin I, Rutherford T and Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemo-resistance in ovarian cancer. *Cancer Res.* 2006; 66(7): 3859-68.
Role: study design, acquisition of data, data analysis, manuscript writing
56. **Alvero AB**, Chen W, Sartorelli AC, Schwartz P, Rutherford T, Mor G. Triapine (3-aminopyridine-2-carboxyaldehyde thiosemicarbazone) induces apoptosis in ovarian

cancer cells. *J Soc Gynecol Investig.* 2006; 13(2): 145-152.

57. **Alvero AB**, O'Malley D, Brown D, Kelly G, Chen W, *Garg M, Rutherford T, Mor G. Molecular mechanism of Phenoxodiol-induced apoptosis in ovarian cancer cells. *Cancer.* 2006; 106(3): 599-608.
58. Sapi E, **Alvero AB**, Chen W, O'Malley D, Hao XY, Dwipoyono B, *Garg M, Kamsteeg M, Rutherford T, Mor G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. *Oncol Res.* 2004; 14(11-12): 567-578.
Role: study design, acquisition of data, data analysis, manuscript writing
59. Krikun G, Mor G, **Alvero A**, Guller S, Schatz F, Sapi E, Rahman M, Caze R, Qumsiyeh M, Lockwood CJ. A novel immortalized human endometrial stromal cell line with normal progestational response. *Endocrinology.* 2004; 145(5): 2291-2296.
Role: study design, acquisition of data, data analysis
60. **Alvero AB**, Fishman DA, Qumsiyeh MB, *Garg M, Kacinski BM, Sapi E. Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. *J Soc Gynecol Investig.* 2004; 11(8): 553-561.
61. **Alvero AB**, Burtneess B, Sapi E. Improved method for the detection of cytokeratin 19 – positive cells in the peripheral blood of breast cancer patients. *Lab Invest.* 2004; 84(5): 658-661.

Review Articles

1. Chehade H, Tedja R, Ramos H, Bawa TS, Adzibolosu N, Gogoi R, Mor G, **Alvero AB**. Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression. *Cancers,* 2022; 14(9):2267.
2. Mor G, Aldo P, **Alvero AB**. The unique immunological and microbial aspects of pregnancy. *Nat Rev Immunol* 2017; 17(8):469-482.
3. Cardenas C, **Alvero AB**, Yun BS, Mor G. Redefining the origin and evolution of ovarian cancer: a hormonal connection. *Endocr Relat Cancer* 2016; 23(9):R411-22.
4. Mor G and **Alvero A**. The duplicitous origin of ovarian cancer. *Rambam Maimonides Med J.* 2013; 4 (1):e0006.
5. Mor G, Yin G, Chefetz I, Yang Y, and **Alvero A**. Ovarian cancer stem cells and inflammation. *Cancer Biol Ther.* 2011; 11 (8): 708-13.
6. **Alvero AB**. Recent insights into the role of NF-kappaB in ovarian carcinogenesis. *Genome Med.* 2010; 2(8): 56.
7. Silasi, DA, **Alvero, AB**, et al. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. *Expert Opin Pharmacother.*

2009; 10 (6): 1059-67.

8. Kim, K, Visintin, I, **Alvero, AB**, Mor, G. Development and validation of a protein-based signature for the detection of ovarian cancer. *Clin Lab Med*. 2009; 29(1): 47-55.

9. **Alvero, AB**, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, and Mor G. Anti-tumor activity of phenoxodiol: from bench to clinic. *Future Oncol*. 2008; 4(4):475-82.

10. Chen R, **Alvero AB**, Silasi DA, Steffensen KD, Mor G. Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells. *Oncogene*. 2008; 27(2):225-33

Book Authorships, Editorships, and Chapters

1. **Alvero AB** and Mor G, eds. DETECTION OF CELL DEATH MECHANISMS *Methods in Molecular Biology*. Human Press. 2021.

2. Tedja R, Fox A, **Alvero AB**. Detection of Anoikis using cell viability dye and quantification of caspase activity. *Methods Mol Biol* 2021; 2255:69-76.

3. Chehade H, Fox A, Mor G, **Alvero AB**. Subcellular fractionation to demonstrate activation of intrinsic apoptotic pathway. *Methods Mol Biol* 2021; 2255: 21-26.

4. Paridon A, Fox A, Mor G, **Alvero AB**. Detection of unfolded protein response by PCR. *Methods Mol Biol* 2021; 2255: 13-20.

5. Chehade H, Fox A, Mor G, **Alvero AB**. Determination of caspase activation by western blot. *Methods Mol Biol* 2021; 2255: 1-12.

6. Yang-Hartwich Y, Bingham J, Garofalo F, **Alvero AB**, Mor G. Detection of p53 protein aggregation in cancer cell lines and tumor samples. *Methods Mol Biol* 2015; 1219:75-86

7. Yang-Hartwich Y, Romanoff E, Bingham J, **Alvero AB**, Mor G. Detection of p53 protein transcriptional activity by chromatin immunoprecipitation. *Methods Mol Biol* 2015; 1219:87-93.

8. Mor G and **Alvero AB**, eds. APOPTOSIS AND CANCER *Methods in Molecular Medicine*. Human Press. 2007 Vol. 414.

9. **Alvero AB**, Montagna MK, and Mor G . Correlation of caspase activity and in vitro chemo-response in epithelial ovarian cancer cell lines. *Apoptosis and Cancer: Methods in Molecular Medicine Series*. 2007; 414:79-82.

10. Silasi D, **Alvero AB**, Mor J, Chen R, Fu HH, Montagna MK and Mor G. Detection of cancer-related proteins in fresh-frozen ovarian cancer samples using Laser capture micro-dissection. *Apoptosis and Cancer: Methods in Molecular Medicine Series*. 2007; 414:35-46.

11. Mor G, Montagna MK, **Alvero AB**. Modulation of Apoptosis to Reverse

Chemoresistance. Apoptosis and Cancer: Methods in Molecular Medicine Series. 2007; 414:1-12.

12. Chen R, **Alvero AB**, Silasi DA, and Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. *Am J Reprod Immunol*. 2007; 57(2): 93-107.

13. Mor G, Fu HH, and **Alvero AB**. Phenoxodiol, a novel approach for the treatment of ovarian cancer. *Curr Opin Investig Drugs*. 2006;7(6): 542-8.

Published Abstracts and presented posters

1. **Alvero AB**, Burtneß B, Sapi E. Quantitative detection of circulating breast cancer cells using real-time RT-PCR. *Proc. Amer. Assoc. Cancer Res*, 2003.

2. **Alvero AB**, Qumsiyeh MB, Garg M, Kacinski BM, Fishman D, Sapi E. Ectopic expression of telomerase prolongs lifespan of normal human ovarian surface epithelial cells without disrupting normal phenotype and growth characteristics. *Proc. Amer. Assoc. Cancer Res*, 2004.

3. **Alvero AB**, Chen W, Sartorelli A, Schwartz P, Rutherford T, Mor G. Triapine (3-aminopyridine-2-carboxyaldehyde thiosemicarbazone) induces apoptosis in chemo-resistant ovarian cancer cells. *Proc. Amer. Assoc. Cancer Res*, 2004.

4. **Alvero AB**, Rutherford T, Mor G. Phenoxodiol-induced apoptosis depends on the simultaneous activation of the mitochondria and degradation of XIAP. *Proc. Amer. Assoc. Cancer Res*, 2005.

5. Kelly MG, Visintin I, **Alvero AB**, Abrahams VM, Chan S, Rutherford TJ Rutherford, Mor, Gil. TLR-4 signaling leads to paclitaxel chemo-resistance and poor clinical outcome in epithelial ovarian cancer. *Proc. Amer. Assoc. Cancer Res*, 2005.

6. **Alvero AB**, Mor G. TLR-MyD88 pathway, cytokines and chemoresistance in ovarian cancer cells. *Proc. Amer. Assoc. Cancer Res*, 2006.

7. **Alvero AB**, Visintin I, and Mor G. MyD88-positive ovarian cancer cells regulate monocyte migration and differentiation. *Proc. Amer. Assoc. Repr Immunol*, 2006.

8. **Alvero AB**, Montagna MK, and Mor G. Autophagy precedes caspase-independent cell death in chemo-resistant ovarian cancer cells. *Proc. Amer. Assoc. Cancer Res*, 2007.

9. **Alvero AB**, Montagna MK, Kim KH, and Mor G. mTOR dephosphorylation and Beclin-1 mitochondrial translocation activates a caspase-independent programmed cell death and overcomes apoptosis resistance in ovarian cancer cells. *Proc. Amer. Assoc. Cancer Res*, 2008.

10. **Alvero AB**, Chen R, Fu HH, et al. Identification and Characterization of Cancer Stem Cells in Ovarian Cancer. *Proc. Amer. Assoc. Cancer Res*, 2008.

11. **Alvero AB**, Montagna MK, Brown DM, et al. NV-128, a novel isoflavone derivative, targets the mTOR pathway and induces cell death in epithelial ovarian cancer stem cells. *Proc. Amer. Assoc. Cancer Res*, 2009.
12. **Alvero AB**, Fu HH, Holmberg J, et al. Ovarian cancer stem cells can serve as vascular progenitors. *Proc. Amer. Assoc. Cancer Res*, 2009.
13. Yin G, Chen R, Fu HH, **Alvero AB**, et al. TWISTing Stemness, Inflammation, and Proliferation of Epithelial Ovarian Cancer Cells through MIR199A2/214. *Proc. Amer. Assoc. Cancer Res - Frontiers in Basic Cancer Research*, 2009.
14. Yin G, Craveiro V, Holmberg J, Fu HH, **Alvero AB**, et al. Epithelial-mesenchymal transition generates ovarian cancer stem cells with metastatic potential. *Proc. Amer. Assoc. Cancer Res - EMT and Cancer Progression and Treatment*, 2010.
15. **Alvero AB**, Montagna MK, Holmberg J, Mor G. Specific inhibition of IKK β induces caspase-independent cell death in the ovarian cancer stem cells. *Proc. Amer. Assoc. Cancer Res*, 2010.
16. Montagna MK, **Alvero AB**, Aldo PB, and Mor G. Differential regulation of monocyte differentiation by the ovarian cancer stem cells. *Proc. Amer. Assoc. Repr Immunol*, 2010.
17. **Alvero AB**, Montagna MK, Holmberg JC, Brown D, and Mor G. Depression of mitochondrial bioenergetics is a potent death stimulus in ovarian cancer stem cells. *Proc. Amer. Assoc. Cancer Res*, 2011.
18. Yin G, Craveiro V, Holmberg J, Fu H, **Alvero AB**, and Mor G. Epithelial ovarian cancer stem cells are the source of metastatic progenitor cells. *Proc. Amer. Assoc. Cancer Res*, 2011.
19. Craveiro V, **AB Alvero**, Aldo P, L Liu, and Mor G. A specific subtype of epithelial ovarian cancer cells induce T regulatory cell differentiation. *Proc. Amer. Assoc. Repr Immunol*, 2011.
20. **Alvero AB**, Craveiro V, Holmberg J, Yang Y, and Mor G. Paclitaxel selects and enriches for CD44+/MyD88+ ovarian cancer stem cells. *Proc. Amer. Assoc. Cancer Res*, 2012.
21. **Alvero AB**, Sumi N, Craveiro V, Joo W, Yang Y, and Mor G. ME-344 delays tumor kinetics in an ovarian cancer in vivo recurrence model. *Proc. Amer. Assoc. Cancer Res*, 2013.
22. Alvero AB, Montagna MK, Sumi N, Joo W, Craveiro V, Graham E, and Mor G. Inability of putative ovarian cancer stem cells to engage OXPHOS confer 2-deoxyglucose-mediated prevention of in vivo recurrence. *Proc. Amer. Assoc. Cancer Res*, 2014.
23. Mor G, Lima E, Sumi N, Pitruzzello M, Yang-Hartwich Y, Brown D, Heaton A, and **Alvero AB**. Cantrixil targets ovarian cancer stem cells and prevents recurrence in a cisplatin-resistant animal model. *Proc. Amer. Assoc. Cancer Res*, 2015.
24. **Alvero AB**, Pitruzzello M, Montagna M, Lima E, and Mor G. Bclxl is a key regulator of mitochondria-induced apoptosis in ovarian cancer stem cells. *Proc. Amer. Assoc. Cancer Res*, 2015.

25. Yang-Hartwich Y, Cardenas C, Pitruzzello M, Lima E, **Alvero AB**, and Mor G. Targeting p53 aggregation in ovarian cancer chemoresistant cells. *Proc. Amer. Assoc. Cancer Res*, 2015.
26. Lilischkis K, Heaton A, **Alvero A**, Mor G, and Brown D. Preclinical toxicology of TRXE-002-1. *Proc. Amer. Assoc. Cancer Res*, 2016.
27. **Alvero AB**, Lima E, Kim D, Orton S, Lee Sumi N, Pitruzzello M, Yang-Hartwich Y, Silasi DA, Fahmy T, and Mor G., Targeting tumor-associated neovasculature for delivery of optical enhancers detects ovarian cancer micrometastasis. *Proc. Amer. Assoc. Cancer Res*, 2016.
28. Yang-Hartwich Y, Tedja R, Bingham J, Gurrea-Soteras M, **Alvero A**, and Mor G. p53-promoted Twist1 degradation inhibits EMT in ovarian cancer cells. *Proc. Amer. Assoc. Cancer Res*, 2016.
29. Cardenas C, **Alvero AB**, Pitruzzello M, Tedja R, Mor G. The omentum promotes ovarian cancer cell survival by increasing cell cycle duration and chemoresistance. *Proc. Amer. Assoc. Cancer Res*, 2017.
30. Tedja R, **Alvero AB**, Cardenas C, Pitruzzello M, Yin G, Yang-Hartwich Y, Roberts C, Glackin C, and Mor G. PKC α -induced Twist1 phosphorylation is a novel regulator of Twist1 stabilization. *Proc. Amer. Assoc. Cancer Res*, 2017.
31. Tedja R, Ventura A, **Alvero AB**, Edelson R, and Mor G. Transimmunization reverses immune tolerance and improves survival in an ovarian cancer mouse model. *Proc. Amer. Assoc. Repro Immunol*, 2017.
32. **Alvero AB**, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Edelson R, and Mor G. Transimmunization prevents recurrence and reprograms the immune milieu in a mouse model of ovarian cancer. *Proc. Amer. Assoc. Cancer Res*, 2019.
33. Chehade H, Aras S, Fox A, Purandare N, Grossman L, Mor g, **Alvero AB**. MNRR1 confers anoikis resistance and metabolic flexibility in ovarian cancer cells. MARTS 2021
34. **Alvero AB**, Fox A, Nakaar V, Yarovinski T, Krady M, Almassian B, Mor, G. AVIDIO- VLV oncolytic virus prevent recurrence in a syngeneic model of recurrent ovarian cancer. *Proc Amer. Assoc. Cancer Res*, 2021.
35. Corey L, **Alvero AB**, Tiwari N, You Y, Rattan R, Kim S, Mor G, Gogoi R. Differentially expressed genes in platinum- resistant high-grade serous ovarian cancer. SGO Annual Meeting, 2021.
36. Walker C, Nguyen TM, Jessel S, Alvero AB, Draghici S, Rutherford T, Mor G. Combining the biomarkers macrophage inhibitory factor, osteopontin and prolactin with CA-125 improves early detection of ovarian cance. SGO Annual Meeting, 2021.
37. Harper A, Fox A, Alvero AB, Gogoi R, Garafalo S, Mor G. VisudyneTM: A new therapeutic strategy for the treatment of ovarian cancer. SGO Annual Meeting, 2021 .
38. **Alvero AB**, Fox A, Madina B, Nakaar V, Yarovinski T, Krady M , Almassian B, Mor G. CARG-2020 a novel immune-modulatory approach to prevent recurrent ovarian cancer. *Proc Amer Assoc Cancer Research*, 2022.

39. Ramos H, Galoforo S, You Y, Mor G, **Alvero AB**, Gogoi R. Connective Tissue Growth Factor Expression Maintains the Epithelial Phenotype of Ovarian Cancer in Early Epithelial to Mesenchymal Transition. ASCO Annual Meeting, 2022.
40. **Alvero AB**, Rattan R, Hou Z, Galoforo S, Fox A, Kim K, Ali-Fehmi R, Kheil M, Morris R, Matherly L, Mor G, and Gogoi R. BRCA1 AND BRCA2 mutations lead to differential Wnt signaling in ovarian cancer cells. IGCS Annual Meeting, 2022.
41. Chehade H, Purandare N, Fox A, Grossman L, Mor G, **Alvero AB**. Loss of MNRR1 inhibits spheroid formation and improves survival in an ovarian cancer syngeneic model. EORTC-AACR-NCI Annual Symposium, 2022.
42. Adzibolusu N, **Alvero AB**, Tedja R, Gogoi R, Morris R, Anderson M, Draghici S, Rutherford T, Mor G. Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. SGO Annual Meeting, 2023.
43. Tedja R, Zhang Y, Chehade H, Fox A, Millman M, Anderson M, Rutherford R, Zhang Z, Chopp M, Mor G, **Alvero AB**. Adipose-derived exosomal miR-421 induces epigenetic reprogramming in ovarian cancer cells by targeting CBX7. SGO Annual Meeting, 2023.
44. **Alvero AB**, Fox A, Madina B, Krady M, Gogoi R, Yarovinsky T, Nakaar V, Almassian B, Mor G. Immune modulation of innate and adaptive responses by CARG-2020 restore immunosurveillance and establish anti-tumoral immunological memory. SGO Annual Meeting, 2023.
45. Gogoi R, Fox A, Thulluri R, Kim S, Adzibolusu N, Mor G, **Alvero AB**. BRCA1 and BRCA2 mutant ovarian tumors create distinct tumor immune microenvironment. 7th International Cancer Immunotherapy Conference: Translating Science into Survival, 2023.
46. Arias D, Swanson G, Adzibolusu N, Fox A, Silasi DA, **Alvero AB**, Mor G. Interferon-stimulated gene signature differentiates immune resistant and immune sensitive ovarian cancers. Heartland Association of Gynecologic Oncology Annual Meeting, 2024.

PRESENTATIONS

Invited Lectures/Presentations

International/National

2023: Annual Meeting of the Society of Gynecologic Oncology
Tampa, FL

“Immune modulation of innate and adaptive responses by CARG-2020 restore immunosurveillance and establish anti-tumoral immunological memory”

2019: Annual Meeting of the American Society for Reproductive Immunology
Grand Rapids, MI

“Transimmunization mobilizes effective anti-tumor immune responses in ovarian cancer”

2017: Annual Meeting of the American Society for Reproductive Immunology
Chicago, IL

“Transimmunization reverses immune tolerance and improves survival in an ovarian cancer mouse model”

- 2013: Incucyte user group meeting, Cambridge, MA
“Ovarian cancer stem cells and tumor repair”
- 2012: Discovery on Target Conference,
Boston, MA, USA
“Targeting mitochondrial bioenergetics potently induces cell death in ovarian cancer stem cells”
- 2010: 1st World Congress on Targeting Mitochondria, Berlin, Germany
“Targeting the mitochondria activates two independent pathways leading to caspase-independent cell death in ovarian cancer stem cells”
- 2008: Annual Meeting of the American Association for Cancer Research,
San Diego, CA, USA
“mTOR dephosphorylation and Beclin-1 mitochondrial translocation activate caspase-independent programmed cell death in ovarian cancer cells”
- 2006: Annual Meeting of the American Society for Reproductive Immunology,
Nashville, TN, USA
“MyD88-positive ovarian cancer cells regulate monocyte migration and differentiation”
- 2002: Department of Biology and Environmental Sciences,
University of New Haven, West Haven, CT, USA:
“Novel Approaches for the Analysis of Gene Expression”

Invited Seminars

- 2023: Molecular Therapeutics Program Annual Symposium
Karmanos Cancer Institute, Detroit, MI
“Differential regulation of tumor immune microenvironment by BRCA1 and BRCA2 mutant ovarian tumors”
- 2020: Molecular Therapeutics Program Meeting
Karmanos Cancer Center, Detroit, MI
“Targeting and prevention of recurrent ovarian cancer”
- 2019: C.S. Mott Center Reproductive Sciences Monthly Seminar Series
Wayne State University, Detroit, MI
“Novel approaches to prevent recurrent ovarian cancer”
- 2009: Developmental Therapeutics Research Program Conference,
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA

“How to target the ovarian cancer stem cells”

- 2009: Yale Stem Cell Center Second Annual Retreat,
The Omni Hotel, New Haven, CT, USA,
“Ovarian cancer stem cells can serve as vascular progenitors”
- 2005: Ovarian Cancer Research Program Conference,
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA,
“Molecular mechanism of chemo-resistance in ovarian cancer”
- 2004: Ovarian Cancer Research Program Conference,
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA,
“Molecular mechanism of Triapine-induced cell death in chemo-resistant ovarian
cancer cells”
- 2003: Breast Cancer Research Program Conference,
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA,
“Quantitative detection and clinical correlation of levels of cytokeratin 19-
positive cells in the peripheral circulation of patients with Stage II and III breast
cancer”